

Pipeline Development Status (Clinical Stage)

Generic name	Dev. code	Indication	Original/Licensors	Region	P1	P2	P3	Filed	Approved	Launched
diquafosol sodium	STN1008903 /DE-089C	Dry eye	Merck Sharp & Dohme Corp. (U.S.)	Japan						
A dry eye treatment which stimulates secretion of mucin and aqueous components from the corneal and conjunctival epithelium. Long-lasting drug. Started Phase 3 in March 2020 in Japan..										
sirolimus	STN1010900 /DE-109	Uveitis	Original	U.S.						
				Japan						
				Europe						
				Asia				Apr-2015		
An intravitreal injection with immunosuppressive effect, anti-angiogenic effect, etc. Started an additional Phase 3 in December 2018 in the U.S. Filed for marketing approval in April 2015 in Asia.										
tafluprost/ timolol maleate	STN1011101 /DE-111A	Glaucoma/ Ocular hypertension	Co-development with AGC	China						
A fixed dose combination drug of a prostaglandin F _{2α} derivative and a beta-adrenergic receptor blocker. Launched in Japan in November 2014. Launched successively in European countries since January 2015. Launched successively in Asian countries since April 2016. Started Phase 3 in January 2019 in China.										
omidenepeg isopropyl	STN1011700 /DE-117	Glaucoma/ Ocular hypertension	Co-development with Ube Industries	U.S.				Nov-2020		
				Japan					Nov-2018	
				Asia					Feb-2021	
An EP2 receptor agonist with a new mechanism of action. Started Phase 3 in September 2018 in the U.S. Launched in November 2018 in Japan. Filed successively marketing approval in Asian countries and launched in February 2021 in Korea.										
sepetaprost	STN1012600 /DE-126	Glaucoma/ Ocular hypertension	ONO PHARMACEUTICAL	U.S.						
				Japan		(Phase 2b)				
A prostaglandin analogue eye drop drug product with a novel mode of action that is a dual agonist for both FP and EP3 receptors for the treatment of glaucoma and ocular hypertension. Started an additional Phase 2 in December 2020 in the U.S. Phase 2b completed in Japan.										
atropine sulfate	STN1012700 /DE-127	Myopia	Singapore Health Services, Nanyang Technological University	Japan		(Phase 2/3)				
				Asia						
Muscarinic antagonist which reduces juvenile myopia progression. Started Phase 2/3 in August 2019 in Japan. Completed P2 in April 2020 in Asia.										
—	Dev. code	Indication	Original/Licensors	Region	P1	P2	P3	Filed	Approved	Launched
glaucoma implant device	STN2000100 /DE-128	Glaucoma	Original	U.S.				Jun-2020		
				Europe					Apr-2019	
				Asia				Mar-2020		
				Others				Oct-2020		
A drainage implant device designed to lower and sustain intraocular pressure (IOP) for the treatment of primary open-angle glaucoma through the drainage of aqueous humor. Completed Premarket Approval rolling submission to the FDA in June 2020 and have been additionally discussing with FDA since the end of February 2021 in the U.S. Launched in Europe in April 2019. Filed successively for marketing approval in Asian countries following Korean filing in March 2020. Filed for marketing approval in October 2020 in Canada.										
latanoprost	STN1013001 /DE-130A (Catioprost)	Glaucoma/ Ocular hypertension	Original	Europe						
				Asia						
An ophthalmic emulsion of a prostaglandin F _{2α} derivative, for the treatment of glaucoma and ocular hypertension. Started P3 trials in April 2019 in Europe and Asia.										
—	Dev. code	Indication	Original/Licensors	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil dimesylate	STN1013900 /AR-13324	Glaucoma Ocular hypertension	Aerie	Japan						
A ROCK (Rho-associated kinase) inhibitor. Aerie has developed and sales in the U.S. Started Phase 3 in November 2020 in Japan.										

	Dev. code	Indication	Original/Licensors	Region	P1	P2	P3	Filed	Approved	Launched
—	MD-16	Cataract	Oculentis	Japan						Nov-2020
A toric intraocular lens to treat aphakia after cataract surgery. Launched in November 2020 in Japan.										

The numbering method for development codes has changed. We show both existing development codes (DE-XXX) and new development codes (STNXXXXXXXX).